Induction of Clinical Response Using Rifaximin in Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00603616
Recruitment Status : Active, not recruiting
First Posted : January 29, 2008
Last Update Posted : May 3, 2018
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Scott Lee, University of Washington

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : December 2018